Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Other Unique Bacteria01:18

Other Unique Bacteria

Magnetic bacteria exhibit a directed movement called magnetotaxis, driven by structures called magnetosomes. These magnetosomes consist of chains of magnetic particles made of either magnetite (Fe₃O₄) or greigite (Fe₃S₄) and are organized in a linear conformation by a protein scaffold within invaginations of the cell membrane. The bacteria align along the north–south magnetic field lines, much like a compass needle. They are typically microaerophilic or anaerobic and are commonly found near the...
Mutations01:35

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiosensitization of Glioblastoma by the K-ras Inhibitor RMC-6236.

bioRxiv : the preprint server for biology·2026
Same author

CPSM: an R package for cancer patient survival risk model using transcriptomics and clinical data.

GigaScience·2026
Same author

Temporal Integration of Serum Proteomics, Metabolomics and MRI Tumor Volumetrics via Deep Learning Identifies Systemic Mediators of Glioblastoma Response to Chemoradiotherapy.

Research square·2026
Same author

A Phase 1 Dose-Escalation Trial of Reirradiation for Patients With Recurrent Glioblastoma.

Practical radiation oncology·2026
Same author

Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response After Adjuvant Treatment with Immune Checkpoint Inhibition (ICI) in Patients with Newly Diagnosed Glioblastoma or Gliosarcoma.

medRxiv : the preprint server for health sciences·2026
Same author

Drug Repurposing in Glioblastoma Using a Machine Learning-Based Hybrid Feature Selection Approach.

International journal of molecular sciences·2025

Related Experiment Video

Updated: May 24, 2026

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

Radiosensitization by the novel DNA intercalating agent vosaroxin.

Ira K Gordon1, Christian Graves, Whoon J Kil

  • 1Radiation Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA. igordon@mail.nih.gov

Radiation Oncology (London, England)
|February 29, 2012
PubMed
Summary

Vosaroxin enhances tumor cell radiosensitivity by inhibiting DNA repair and increasing mitotic catastrophe. This novel naphthyridine analog shows promise as a radiation sensitizer in vitro and in vivo.

More Related Videos

Single Molecule Analysis of Laser Localized Psoralen Adducts
11:46

Single Molecule Analysis of Laser Localized Psoralen Adducts

Published on: April 20, 2017

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Related Experiment Videos

Last Updated: May 24, 2026

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

Single Molecule Analysis of Laser Localized Psoralen Adducts
11:46

Single Molecule Analysis of Laser Localized Psoralen Adducts

Published on: April 20, 2017

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Vosaroxin is a novel naphthyridine analog with DNA intercalating and topoisomerase II inhibitory properties.
  • It evades common drug resistance mechanisms, being independent of P-glycoprotein and p53.
  • Its potential as a clinical radiation sensitizer requires investigation.

Purpose of the Study:

  • To evaluate vosaroxin's efficacy as a radiation sensitizer.
  • To investigate its effects on tumor cell radiosensitivity in vitro and in vivo.

Main Methods:

  • Clonogenic assays were used to assess radiosensitivity in U251, DU145, and MiaPaca-2 cells.
  • Mechanistic studies involved flow cytometry for cell cycle and apoptosis, and a gamma-H2AX assay for DNA damage.
  • In vivo studies measured tumor growth delay in a subcutaneous U251 xenograft model.

Main Results:

  • Vosaroxin (50-100 nmol/L) sensitized all tested cell lines, with dose enhancement factors ranging from 1.20 to 1.51.
  • It significantly increased mitotic catastrophe and DNA damage (gamma-H2AX levels) post-irradiation.
  • In vivo, vosaroxin administered 4 hours prior to radiation resulted in an 8.6-day tumor growth delay.

Conclusions:

  • Vosaroxin effectively enhances tumor cell radiosensitivity both in vitro and in vivo.
  • The mechanism involves the inhibition of DNA repair and the induction of mitotic catastrophe.
  • Vosaroxin demonstrates potential as a clinically applicable radiation sensitizer.